Join
Live feed
·
PRReleasevia Quantisnow
Spruce Biosciences Inc. logo

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

ByQuantisnow·Wall Street's wire, on your screen.
SPRB· Spruce Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SPRB (Spruce Biosciences Inc.) and more on Quantisnow.